MIRA Pharmaceuticals, Inc. (MIRA)
MIRA Pharmaceuticals, Inc. operates in the Drug Manufacturers - General industry of the Healthcare sector, headquartered in Miami, FL, US. The stock last traded at $0.75, down 3.47% on the session, giving a market capitalisation of $31.5M. On trailing twelve-month figures it carries a trailing P/E of -0.52, a net margin of 0.0%. Its beta of 1.55 implies it has historically moved more than the broad market.
MIRA Pharmaceuticals, Inc. operates as a biopharmaceutical enterprise currently in the clinical development phase. Its main objective involves the creation and market introduction of a novel synthetic tetrahydrocannabinol (THC) analog. This compound is undergoing investigation for its potential to address anxiety and the cognitive impairments frequently observed in adult patients suffering from early-stage dementia. The firm's lead candidate, MIRA1a, is a synthetic cannabinoid analog engineered to alleviate both anxiety and chronic pain through its interaction with cannabinoid type 1 and type 2 receptors. Originally established in 2020 as MIRA1a Therapeutics, Inc., MIRA Pharmaceuticals, Inc. maintains its headquarters in Baltimore, Maryland.
MIRA Pharmaceuticals, Inc. is most often compared with the following Healthcare names: